The post is an accurate condensation of a real National Geographic article, which exists and was located. The article quotes Mark Mattson (Johns Hopkins neuroscientist), Duane Mellor (dietitian, University Hospitals of Leicester NHS Trust), and Luigi Fontana.

On physiological effects in the body, the evidence is solid. Fasting reliably triggers "metabolic switching," in which liver glycogen is depleted and fatty acids are converted to ketone bodies for fuel. Per Johns Hopkins material citing Mattson, ketones begin appearing roughly 8 to 12 hours into a fast. Insulin falls, hepatic beta-oxidation increases, and mTOR signaling is suppressed. These are measurable, uncontroversial physiological changes.

On clinical benefit, the strongest available evidence is more modest than popular framing. The BMJ 2025 network meta-analysis of 99 randomized trials found that all intermittent fasting strategies and continuous calorie restriction produced weight loss compared with unrestricted eating. Alternate-day fasting was the only fasting variant that beat continuous calorie restriction, by a mean difference of −1.29 kg (95% CI −1.99 to −0.59, moderate certainty). The authors noted this did not reach their pre-defined minimally important clinical threshold of 2 kg for people with obesity. Most outcomes rested on low-to-moderate certainty evidence, trials averaged 12 weeks, and only trials of 24 weeks or longer showed weight benefit versus unrestricted diets. Separate 12-month RCTs found time-restricted eating was not superior to simple calorie counting for weight, body fat, or metabolic risk factors.

On brain effects, the evidence is substantially weaker and is predominantly preclinical. Reviews describe enhanced hippocampal neurogenesis, synaptic plasticity, BDNF and CREB signaling, and reduced neuroinflammation, but these findings come overwhelmingly from rodent models. Notably, the National Geographic article itself contains the qualifier: Mellor states that although many people report sharper thinking, clinical trials have not demonstrated those benefits in healthy individuals. A 2026 randomized trial found fasting did not impair cognition, which is a null safety finding rather than a demonstrated benefit.

On "benefits may not apply to everyone," this is well supported. Mattson and Johns Hopkins explicitly do not recommend intermittent fasting for people with type 1 diabetes, people with eating disorders, people who are underweight, young children, pregnant or breastfeeding women, and frail or elderly adults. The American Diabetes Association nutrition therapy consensus report found intermittent fasting may produce weight loss but did not improve A1C, and does not recommend it as diabetes therapy. Hypoglycemia is a documented risk for people on insulin or insulin secretagogues.